



Contents lists available at ScienceDirect

Asian Pacific Journal of Tropical Biomedicine

journal homepage: www.elsevier.com/locate/apjtb



Document heading

## Anti-hyperlipidemic activity of methanol extracts of three plants of *Amaranthus* in triton-WR 1339 induced hyperlipidemic rats

K Girija\*, K Lakshman

Department of Pharmacognosy, PES College of Pharmacy, Bangalore, Karnataka, India

## ARTICLE INFO

## Article history:

Received 10 July 2011

Received in revised form 5 August 2011

Accepted 28 August 2011

Available online 10 September 2011

## Keywords:

Hypolipidemic

*Amaranthus caudatus**Amaranthus viridis**Amaranthus spinosus*

Serum cholesterol

Serum triglycerides

High density lipoprotein

Low density lipoprotein

## ABSTRACT

**Objective:** To investigate the anti-hyperlipidemic activity of methanol extracts of leaves of three plants of *Amaranthus*. **Methods:** In this study, the anti-hyperlipidemic effects of three plants of *Amaranthus* were evaluated by using normal and triton-WR 1339 induced rats at the dose of 200, 300 and 400 mg/kg *p.o.* The serum harvested was analyzed for total cholesterol, triglycerides, high density lipoprotein and low density lipoprotein. **Results:** It was found that all the three plants at 400 mg/kg dose showed significant anti-hyperlipidemic effect ( $P < 0.01$ ), whereas 300 mg/kg dose is less significant in the entire parameters used for evaluation of anti hyperlipidemic effect ( $P < 0.05$ ). **Conclusions:** Methanol extracts of *Amaranthus caudatus*, *Amaranthus spinosus*, *Amaranthus viridis* showed significant anti-hyperlipidemic effect and this study provides the scientific proof for their traditional claims.

### 1. Introduction

Cardio vascular diseases are leading cause of death in both industrialized and developing nations. Disorders of lipid metabolism, following oxidative stress are the prime risk factors for initiation and progression of these diseases[1]. The current anti-hyperlipidemic therapy includes principally statins and fibrates, the former corrects the altered blood lipid profile by inhibiting the bio-synthesis of cholesterol and the latter acts by enhancing the clearance of triglyceride rich lipo proteins. The investigation on plant drugs will be a useful strategy in the discovery of new lead molecules eliciting improved activity by regulating the different mechanisms maintaining the lipid metabolism and thus can be used in treating hyperlipidemia of varied etiology[2]. Traditional system of medicine like Ayurveda, Unani and Chinese prescribe numerous herbal drugs for cardio vascular disorders. Recently herbal hypolipidemics

have gained importance to fill the lacunae created by the allopathic drugs.

The *Amaranthus* plants are spread throughout the world, growing under a wide range of climatic conditions and they are able to produce grains and leafy edible vegetables. *Amaranthus caudatus* (*A. caudatus*) Amaranthaceae was traditionally used to cure piles, fever, diuretic, leprosy. Methanolic extract of *A. caudatus* showed antinociceptive, antipyretic[3], hepatoprotective activity[4], and *in vitro*-amylase inhibition and antioxidant activity[5]. *Amaranthus spinosus* (*A. spinosus*) Amaranthaceae, is an annual herb, native to tropical America and found as a weed in cultivated lands as well as follow lands throughout India. *A. spinosus* showed chemoprotective, *in vivo* antioxidant activity[6] and *in vitro* alphaamylase inhibition in oxidative stress in diabetic rats[7]. *Amaranthus viridis* (*A. viridis*) Amaranthaceae is a branched glabrous herb, distributed in all tropical countries. The traditional uses are anti-inflammatory, diuretic, anti ulcer, laxative, anti leprotic and asthma[8]. Methanol extract of *A. viridis* showed *in vitro* anthelmintic property[9], hepatoprotective and antioxidant activity[10].

*A. caudatus*, *A. spinosus* and *A. viridis* have been used to reduce the elevated lipid profile in Indian traditional system

\*Corresponding author: K Girija, Assistant Professor, Department of Pharmacognosy, PES College of Pharmacy, 50 Feet Road, Hanumanthnagar, Bangalore-560050, Karnataka, India.

Tel: +91-7795844506

Fax: +91-8026600113

E-mail: girijapes@gmail.com

of medicine. The leaves were selected to investigate the anti hyperlipidemic activity. However there is lack of scientific report, so our aim is to provide scientific validation for traditional claims.

## 2. Materials and methods

### 2.1. Collection of plant material and extraction

The fresh leaves of *A. spinosus*, *A. viridis* and *A. caudatus* were collected from GKVK, Agricultural University, Bangalore, and were authenticated by the taxonomist Dr. Rajanna, GKVK, Bangalore. The voucher specimen (PESCP–26, 27, 28) was deposited in college herbarium. The leaves of *A. spinosus*, *A. viridis* and *A. caudatus* were shade dried and coarsely powdered. The coarse powder (60 g each) was subjected to extraction with methanol by soxhlet apparatus and extracts were concentrated using rotary evaporator under reduced pressure (yield–4.8, 4.4, 4.6 % w/w) and then was stored in a refrigerator at 4 °C, until use for the biological testing and phytochemical screening.

### 2.2. Preliminary phytochemical screening

The methanol extracts of *A. spinosus*, *A. viridis* and *A. caudatus* were screened for the presence of various phytoconstituents<sup>[11]</sup>.

### 2.3. Animals

Healthy wistar rats between 2–3 months of age of either sex and weighing 180–200 g were acclimatised to the laboratory at temperature (25 ± 1) °C, relative humidity (50 ± 15) %, 12 h light - dark cycles, kept in standard polypropylene cages of maximum 2 animals each, given standard diet (Kamadhenu Enterprises, Bangalore) and water ad-libitum in accordance with the instructions given by Institutional Animal Ethical Committee, CPCSEA<sup>[12]</sup>.

### 2.4. Acute toxicity studies

Methanol extracts of *A. spinosus*, *A. viridis* and *A. caudatus* were studied for the acute oral toxicity according to the guideline No. 423 set by Organization for Economic Cooperation and Development (OECD)<sup>[13]</sup>. Healthy wistar rats (150 - 180 g) were used for the study. The two doses of 2000 mg/kg (p.o.) and 5000 mg/kg (p.o.) of the test samples were given to two groups containing 5 animals in each group for three plants. The treated groups were monitored for 14 days, for mortality and general behaviour. The extract was devoid of any toxicity in rats when given in dose up to 5000 mg/kg by oral route. Hence, for further studies 200, 300 and 400 mg/kg doses of extract were selected.

### 2.5. Hypolipidemic activity in normal rats

Animals in the normal control group received normal saline 10 mL/kg orally. Standard group received Atorvastatin at 10 mg/kg orally. The test group of animals were treated with the methanol extracts of *A. caudatus*, *A. spinosus*, *A. viridis* at predetermined therapeutic doses of 200, 300 and 400 mg/kg p.o. The treatments were given for 8 days. The blood samples were withdrawn from retro-orbital plexus. All the lipid profile parameters were determined. Total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides were analysed from serum<sup>[14]</sup>.

### 2.6. Triton induced anti-hyperlipidemic activity

Experimental rats fasted for 18 h were provided water ad-libitum. The rats were divided into 11 groups containing 6 animals each viz. normal control group (NC–Vehicle) received 2% vehicle tween–80 at 5 mL/kg orally, triton control group (TC–Vehicle) received triton–200 dissolved in 2% Tween–80 at 5 mL/kg i.p., Standard group received atorvastatin at 10 mg/kg orally. Methanol extracts of all the three plant groups received three doses of 200, 300 and 400 mg/kg p.o. All the treatments were given immediately after injection of triton WR–1339 except normal control group. In the following period of study (48 h) animals had access only to water.

### 2.7. Biochemical estimation

Blood samples were collected after 0, 24 and 48 h of triton injection by retro-orbital puncture. Blood was immediately centrifuged (2500 rpm for 10 min) and serum was analysed for total cholesterol, triglycerides, HDL and LDL<sup>[14]</sup>.

## 3. Results

### 3.1. Phytochemical screening

The percentage yield of *A. caudatus*, *A. spinosus*, *A. viridis* were found to be 4.6%, 4.8% and 4.4% w/w, respectively. The methanol extract of three plants contained glycosides, saponins, flavonoids, proteins, amino acids and carbohydrates.

### 3.2. Acute toxicity test

The acute oral toxicity test showed the normal behaviour of the treated rats. No toxic effects were observed at a higher dose of 5 g/kg bw. Hence there were no lethal effects and indicated that it may have a reasonable safety margin with regards to acute toxicity.

### 3.3. Hypolipidemic activity in normal rats


The groups treated with methonal extract of *A. caudatus* (MEAC), methonal extract of *A. viridis* (MEAV) showed

significant decrease ( $P < 0.01$ ) in the level of total cholesterol at 400 mg/kg, whereas MEAV showed significant decrease ( $P < 0.05$ ) in the level of total cholesterol at 300 mg/kg. The groups treated with methanol extracts showed significant decrease in the level of triglycerides in MEAC ( $P < 0.05$ ) and MEAV ( $P < 0.01$ ) at 400 mg/kg. The groups treated with methanol extract of *A. spinosus* (MEAS) ( $P < 0.05$ ) at 400 mg/kg, MEAV ( $P < 0.05$ ) at 300 mg/kg and MEAV ( $P < 0.01$ ) at 400 mg/kg showed significant increase in the level of HDL. The level of LDL significantly decreased in MEAV ( $P < 0.01$ ) treated groups at 400 mg/kg and ( $P < 0.05$ ) at 300 mg/kg, and MEAS ( $P < 0.05$ ) at 300 mg/kg respectively.

### 3.4. Anti-hyperlipidemic activity in triton induced hyperlipidemic rats

#### 3.4.1. Effect on serum level of total cholesterol


The groups treated with MEAC, MEAS and MEAV showed significant decrease ( $P < 0.01$ ) in the level of total cholesterol at 400 mg/kg after 24 h and 48 h (Figure 1).



**Figure 1.** Effect of *A. caudarus*, *A. viridis*, *A. spinosus* on serum cholesterol level in Triton WR-1339 induced hyperlipidemic rats. Value are expressed as Mean  $\pm$  SEM.  $n=6$ . Significant values were compared with  $*P < 0.05$  and  $**P < 0.01$  triton control vs all groups.

#### 3.4.2. Effect on serum level of triglycerides

The level of triglycerides significantly increased ( $P < 0.01$ ) in MEAC and MEAV at 400 mg/dL and MEAV ( $P < 0.05$ ) at 300 mg/dL after 24 h and 48 h (Figure 2).




**Figure 2.** Effect of *A. caudarus*, *A. viridis*, *A. spinosus* on serum triglyceride level in Triton WR-1339 induced hyperlipidemic rats. Value are expressed as Mean  $\pm$  SEM.  $n=6$ . Significant values were compared with  $*P < 0.05$  and  $**P < 0.01$  triton control vs all groups.

#### 3.4.3. Effect on serum level of HDL

The groups with MEAC, MEAV showed significant increase ( $P < 0.01$ ) in the level of HDL at 400 mg/dL, whereas MEAV


( $P < 0.05$ ) increase in HDL level at 300 mg/dL after 24 h and 48 h (Figure 3).



**Figure 3.** Effect of *A. caudarus*, *A. viridis*, *A. spinosus* on serum HDL level in Triton WR-1339 induced hyperlipidemic rats. Value are expressed as Mean  $\pm$  SEM.  $n=6$ . Significant values were compared with  $*P < 0.05$  and  $**P < 0.01$  triton control vs all groups.

#### 3.4.4. Effect on serum level of LDL

The level of LDL significantly decreased ( $P < 0.01$ ) in MEAV at 400 mg/dL, ( $P < 0.05$ ) at 300 mg/dL after 24 h and 48 h (Figure 4).



**Figure 4.** Effect of *A. caudarus*, *A. viridis*, *A. spinosus* on serum LDL level in Triton WR-1339 induced hyperlipidemic rats. Value are expressed as Mean  $\pm$  SEM.  $n=6$ . Significant values were compared with  $*P < 0.05$  and  $**P < 0.01$  triton control vs all groups.

#### 3.4.5. Effect on atorvastatin on lipid profile

Atorvastatin (10 mg/kg) group showed significant decrease ( $P < 0.01$ ) in the level of triglycerides, total cholesterol and LDL after 24 hr and 48 hr and significant increase ( $P < 0.01$ ) in the level of HDL after 24 h and 48 h.

## 4. Discussion

Triton WR-1339 acts as a surfactant and suppresses the action of lipases to block the uptake of lipoproteins from circulation by extra hepatic tissues, resulting into increased blood lipid concentration[15]. The biphasic nature of triton - induced hyperlipidemia is helpful in understanding the mode of action of hypolipidemia agents. Drugs interfering with lipid biosynthesis or uptake will be active in the synthesis phase and metabolism will be active in the excretory phase. In the present study, the methanol extracts of three plants reduced the cholesterol and triglycerides in a manner similar to the reduction facilitated by atorvastatin. The hypolipidemic activities of atorvastatin and the

methanol extract of three plants of *Amaranthus* were evident in both synthesis and excretory phases of triton-induced hyperlipidemia in rats. Triton induces hyperlipidemia by increasing the hepatic synthesis of cholesterol and triglycerides<sup>[16,17]</sup>. So, it can be assumed that *Amaranthus* inhibits the biosynthesis of cholesterol and triglycerides and therefore can be used for the prevention (prophylactic) of hyperlipidemia.

In fact, flavonoids, steroids, saponins and anthocyanin, a heterogeneous group of ubiquitous plant polyphenols have exhibited a variety of pharmacological activities including the anti-atherogenesis. The plant steroids reduce the absorption of cholesterol and thus increase faecal excretion of cholesterol<sup>[18]</sup>. Lupeol, a triterpenoid was reported for its cardioprotective activity against experimental hypercholesterolemia<sup>[19]</sup>. In the present study, methanol extraction of leaves of three plants of *Amaranthus* reduces the level of cholesterol, triglycerides and LDL and increase the level of HDL, which may probably be due to the presence of steroids, flavonoids and triterpenoids, since all the extracts of *Amaranthus* showed the presence of phytoconstituents like steroids, flavonoids and triterpenoids.

Hence the present study confirms the significant antihyperlipidemic potential of three plants of *Amaranthus* owing to its ability to reduce level of total cholesterol, triglycerides, LDL and increasing HDL level. *A. viridis* showed highly significant anti-hyperlipidemic activity compared to *A. caudatus* and *A. spinosus* in triton induced hyperlipidemia in rats. Further studies to isolate, identify and characterize the active principle(s) are in the progress. The antihyperlipidemic activity may be attributed to some of its active principles.

### Conflict of interest statement

We declare that we have no conflict of interest.

### Acknowledgements

The authors are thankful to Dr. S Mohan, Director and Principal and management, PES College of Pharmacy, Bangalore-560050 for their kind permission to publish this work.

### References

- [1] Sharma N, Garg V. Antidiabetic and antioxidant potential of ethanolic extract of *Butea monosperma* leaves in alloxan-induced diabetic mice. *Indian J Biochem Biophys* 2009; **46**(1): 99–105.
- [2] Robert WM, Thomas V. Anti hyperlipidemic agent. In: Brunton LL, Lazo SJ, editors. *Goodman and Gillman's the pharmacological basis of therapeutics*. 11th ed. New York: Mc Graw-Hill; 2006: 933.
- [3] Ashok Kumar BS, Lakhman K, Jayaveera KN. Antinociceptive and antipyretic activities of methanol extract *Amaranthus caudatus*. *Lat Am J Pharm* 2010; **29**: 635–639.
- [4] Ashok Kumar BS, Lakhman K. Hepatoprotective activity of methanol extract of *Amaranthus caudatus* against paracetamol induced hepatic injury in rats. *Chin J Integr Med* 2011; **9**: 194–200.
- [5] Lakshman K. *In vitro*-amylase inhibition and antioxidant activities of methanolic extract of *Amaranthus caudatus*. *Oman Med J* 2011; **26**:166–170.
- [6] Ashok Kumar BS, Lakhman K, Jayaveera KN. Chemoprotective and *in vivo* antioxidant activities of *Amaranthus spinosus*. *Acta Med Salania* 2010; **39**: 68–74.
- [7] Ashok Kumar BS, K Lakhman. *In vitro* alpha amylase inhibition and *in vivo* antioxidant potential of *Amaranthus spinosus* in alloxan induced oxidative stress in diabetic rats. *Saudi J Biol Sci* 2011; **18**: 1–5.
- [8] Maria de Fatima Agra, Nurisilva K, Ionaldo Jose Lima DinizBasilio, Patricia Franca De Freitas, Jose Maria Barbosa Filho. Survey of medicinal plants used in the region north-east of Brazil. *Braz J Pharmacogn* 2008; **18**(3): 472–508.
- [9] Lakshman K. Hepatoprotective and antioxidant activities of *Amaranthus viridis*. *Maced J Med Sci* 2011; 1–6.
- [10] Ashok Kumar BS, K Lakhman, KN Jayaveera. *In vitro* anthelmintic property of methanol extract of *Amaranthus viridis*. *Electron J Env Agr Food Chem* 2010; **9**: 1093–1097.
- [11] Harborne JB. *Phytochemical methods*. 3rd ed. London: Chapman & Hall; 1998.
- [12] PHS. Public health service policy on human health care and use laboratory animals. Washington D.C: U.S. Department of Health and Human Services; 1996.
- [13] OECD. Guidelines for the testing of chemicals revised draft guideline 423: Acute oral toxicity. France: Organization for Economic Cooperation and Development; 2000.
- [14] Vogel WH, Scholkens BA, Sandow J, Muller G. *Drug discovery and evaluation*. 2nd ed. New York: Springer-Verlog Berlin Hiedelberg; 2002, p. 1103–1104.
- [15] Kumar V, Khan MM, Khann AK, Singh R, Chander R, Mahdi F, et al. Lipid lowering activity of *Anthocephalus indicus* root in hyperlipidemic rats. *Evid Based Complement Alternat Med* 2010; **7**(3): 317–322.
- [16] Vogel HG, Vogel WH. *Drug discovery and evaluation- Pharmacological assays*. New York: Springer-Verlag Berlin Hiedelberg; 1997, p. 598.
- [17] Kumar S, Kumar V, Prakash O. Antidiabetic, hypolipidemic and histopathological analysis of *Dillenia indica* (L.) leaves extract on alloxan induced diabetic rats. *Asian Pac J Trop Med* 2011; **4**(5): 347–352.
- [18] Del Bas JM, Fernandez-Larrea J, Blay M, Ardevol A, Arola MJ, Blade C. Grape seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in healthy rats. *FASEB J* 2005; **19**(3): 479–481.
- [19] Sudhakar V, Kumar SA, Sudharshan PT, Varalakshmi P. Protective effect of lupeol and its ester on cardiac abnormalities in experimental hypercholesterolemia. *Vascul pharmacol* 2007; **46**(6): 412–418.